vimarsana.com
Home
Live Updates
First Presentations of Phase 3 Data for Bimekizumab Across t
First Presentations of Phase 3 Data for Bimekizumab Across t
First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022
/PRNewswire/ -- UCB, a global pharmaceutical company, today announced new 24-week data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, evaluating...
Related Keywords
United States ,
Denmark ,
Copenhagen ,
Køavn ,
United Kingdom ,
Brussels ,
Bruxelles Capitale ,
Belgium ,
Smyrna ,
Izmir ,
Turkey ,
Emmanuel Caeymaex ,
Musculoskelet Disord ,
Eimear Obrien ,
Antje Witte ,
J Clin Pharmacol ,
Immunology Solutions ,
European Congress ,
Brand Communications ,
Twitter ,
Ucb Inc ,
Drug Administration ,
Assessment Of Spondyloarthritis International Society ,
Corporate Communications ,
Source Ucb Inc ,
Executive Vice President ,
Spondyloarthritis International Society ,
Open Label Extension ,
Euronext Brussels ,
Subjects With Active Ankylosing Spondylitis ,
With Bimekizumab ,
Patients With Active Ankylosing Spondylitis ,
Results From ,
Ann Rheum ,
Long Term Safety ,
Subjects With Ankylosing Spondylitis ,
Axial Spondyloarthritis ,
Active Psoriatic Arthritis ,
Ucb ,
Nc ,